Global Blood Therapeutics Investor Webcast from the American Society of Hematology Annual Meeting

Mon, Dec 5, 2016 12:15 PM PST

Global Blood Therapeutics Investor Webcast from the American Society of Hematology Annual Meeting

Mon, Dec 5, 2016 12:15 PM PST

 

During the live and archived event, Global Blood Therapeutics will highlight data presented at the ASH meeting from GBT’s ongoing Phase 1/2 GBT440-001 trial including results of dosing GBT440 at 900 mg per day in SCD patients for up to 6 months, and the metabolism of GBT440 in healthy subjects, as well as the methodology utilized to develop the Patient Reported Outcome (PRO) tool that will be used in the HOPE (Hemoglobin Oxygen Affinity Modulation to Inhibit HbS PolymErization) Study.

Speakers:
Ted W. Love, M.D.
Chief Executive Officer of GBT

Jo Howard MRCP., FRCPath 
Honorary Reader in Haemoglobin Opathy, Guy’s and St Thomas’ NHS Foundation Trust

Wally R. Smith, M.D. 
Virginia Commonwealth University Medical Center

Jeremy Hobart PhD FRCP
Professor of Clinical Neurology and Health Measurement, Peninsula College of Medicine and Dentistry 


close log in form button
Log In Now Not Registered?

close register form button
Register Now Already Registered?